

B




Fig.S1 Synthetic route (A) and ¹H NMR (B) of ATF-PEG-DSPE

Table S1 Structural properties and drug content of the liposomes prepared in this study.

Preparations	Size/nm	PDI	Zeta potential/mV	Drug loading (%)	Encapsulation efficiency (%)	Drug content(μg/mL)
Pt Lps	96.32±0.4957	0.148±0.003	-15.9±1.57	5.45%±0.05%	97.1%±2.6%	229.95±22.53
ATF @ Pt Lps	100.5±0.2517	0.168±0.004	-12.5±0.917	4.32%±0.12%	95.3%±3.5%	203.52±17.95




Fig. S 2 TEM images of Pt Lps(A) and ATF@Pt Lps(B) under pH=6.8 environment.




Fig. S3 Fluorescence microscope images of uPAR receptor expression in PANC02 cells under 60× magnification.




Fig. S4 Cell viability of PANC 02 cells treated with different liposome formulations.




Fig. S5 (A) Photograph of colony formation assay and (B) the data analysis of the number of colonies per well treated with the different liposomes.




Fig. S6 Cell viability of NIH/3T3 cells treated with different liposome formulations.




Fig. S7 Fluorescence microscope images (Magnification=40×) of DAPI-labeled nucleus and Cy5-labeled anti-PD-1 (red) with endothelial cells labeled with FITC-conjugated CD31 antibody (green) in different depth tumor sections




Fig. S8 Body weight changes curve of Panc 02 tumor-bearing mouse models.




Fig. S9 Tumor growth curve of tumor-bearing mice receiving different dosage cisplatin.




Fig. S10 Images of kidney slices stained by HE.




Fig. S11 ELISA analysis of the intratumoral release of TNF- α after the different treatments.




Fig. S12 ELISA analysis of the intratumoral release of IFN- γ after the different treatments.